Literature DB >> 1673144

Membrane cofactor protein of the complement system. A HindIII restriction fragment length polymorphism that correlates with the expression polymorphism.

N S Bora1, T W Post, J P Atkinson.   

Abstract

An RFLP was found in the DNA of 25 unrelated persons, two families, and five cell lines that correlated with their membrane cofactor protein phenotype. If restricted with HindIII, DNA derived from upper band predominant protein (U) phenotypes had a band at 2 kb, whereas DNA of lower band predominant (L) phenotypes had a 4-kb band. The equal band protein phenotype, in which equal quantities of the two species are expressed, had bands at both 4 and 2 kb. The polymorphic HindIII site was localized to an intron within the membrane cofactor protein gene between exon 1 (codes for 5'UT/signal peptide) and exon 2 (codes for the first short consensus repeat). Using the polymerase chain reaction (PCR), sequences around this site were amplified and a single band of 260 bp was produced. In the U phenotype, the PCR product was restricted with HindIII into 200- and 60-bp fragments. In the L phenotype, there was no change in the size of 260 bp upon restriction with HindIII. For the equal band protein phenotype, the PCR product was partially cleaved. The 260-bp PCR product was subcloned and sequenced. DNA from the U phenotype demonstrated an intact HindIII site (AAGCTT), whereas in the DNA of the L phenotype, this site was altered because a "G" was substituted for a "C" (AAGGTT).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Strong associations between RFLP and protein polymorphisms for CD46.

Authors:  A N Wilton; R W Johnstone; I F McKenzie; D F Purcell
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 2.  Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor.

Authors:  J P Atkinson; T J Oglesby; D White; E A Adams; M K Liszewski
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Identification and quantification of complement regulator CD46 on normal human tissues.

Authors:  R W Johnstone; B E Loveland; I F McKenzie
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

4.  Restriction fragment length polymorphism of the membrane cofactor protein gene in patients with rheumatic diseases.

Authors:  S Shiokawa; M Yasuda; M Nobunaga
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

5.  Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP).

Authors:  J M Pérez De La Lastra; C W Van Den Berg; R Bullido; F Almazán; J Domínguez; D Llanes; B P Morgan
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

6.  Membrane cofactor protein (MCP; CD46) expression in transgenic mice.

Authors:  C Kemper; M Leung; C B Stephensen; C A Pinkert; M K Liszewski; R Cattaneo; J P Atkinson
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

7.  Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.

Authors:  K L Simpson; A Jones; S Norman; C H Holmes
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

8.  Complement regulatory proteins in early human fetal life: CD59, membrane co-factor protein (MCP) and decay-accelerating factor (DAF) are differentially expressed in the developing liver.

Authors:  K L Simpson; J M Houlihan; C H Holmes
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

9.  Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype.

Authors:  T W Post; M K Liszewski; E M Adams; I Tedja; E A Miller; J P Atkinson
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.